GKOS (US)

With medtech and biopharma companies set to descend on San Francisco next week, below we provide a set of significant policy-related questions for clients to ask management, the answers to which will inform company growth…

Yesterday’s Medicare Administrative Contractor (MAC) advisory committee (CAC) meeting on GKOS’s iDose bolsters our relatively sanguine outlook going into the event [here, here], and would expect any headwinds from a likely mid-2026 draft local coverage…

The questions to be addressed at a November 12 Contractor Advisory Committee (CAC) on GKOS’s iDose bolster our expectations for real, but likely manageable, headwinds via an eventual local coverage determination (LCD), which we suspect…

We view the weakness in GKOS shares this week as somewhat overdone following the announcement that iDose will be the subject of a Nov. 12 Contractor Advisory Committee (CAC) meeting among five Medicare Administrative Contractors…

With GKOS shares down pre-market amid questions on its earnings call last night regarding the Medicare policy issues affecting iDose and iStent sales, we offer the following takeaways: We generally agree with the company that,…

With medical device, equipment, diagnostics, and life science tools (LST) companies set to descend on San Francisco next week for a key investor conference, below we provide a set of significant policy-related questions for clients…